• Adaptive Biotechnologies flagged clonoSEQ MRD test data across 33 presentations scheduled for ASCO May 29–June 3, 2026, and EHA June 11–14, 2026.
• Presentations are set to position clonoSEQ as a decision-support tool for response assessment, ongoing monitoring, and MRD-guided treatment choices in blood cancers.
• Updates include follow-on results from multiple myeloma trials, including a final CEPHEUS analysis tied to an FDA decision that relied on an MRD endpoint.
• CLL studies are expected to show MRD-guided therapy stopping strategies can support durable time off treatment in selected patients.
• ALL findings are slated to indicate clonoSEQ can detect residual disease more reliably than flow cytometry, improving outcome prediction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605290730PRIMZONEFULLFEED9728696) on May 29, 2026, and is solely responsible for the information contained therein.